Eidos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

06.22.2018

Eidos Therapeutics Announces Pricing of Initial Public Offering

06.20.2018

NeuroVive Out-Licenses Targeted LHON Therapy to BridgeBio Pharma’s New Subsidiary Fortify Therapeutics

06.18.2018

BridgeBio Pharma launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

06.13.2018

PellePharm to Participate in the Cantor Fitzgerald Dermatology and Aesthetics Summit

06.13.2018

BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy

06.11.2018

PellePharm to Present at the 2018 UBS Global Healthcare Conference

05.21.2018

PellePharm to Present Topical Patidegib and Skin Cancer Epidemiological Data at the 7th International Investigative Dermatology Meeting

05.16.2018

Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

05.03.2018

Eidos Therapeutics Completes $64M Series B Financing

04.05.2018

Eidos Therapeutics to Host Symposium on TTR Stabilization at the 16th International Symposium on Amyloidosis

03.20.2018

BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

01.30.2018

Eidos Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

01.05.2018

BridgeBio Pharma Appoints Sanuj Ravindran, M.D., and Eric Michael David, M.D. as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programs

01.04.2018

PellePharm Appoints Sanuj K. Ravindran, M.D., as President and Chief Executive Officer

01.04.2018

FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to PellePharm for Topical Patidegib in Gorlin Syndrome

11.20.2017

Preclinical Data Demonstrates Potential of Eidos Therapeutics’ Lead Compound for the Treatment for Transythyretin Amyloidosis

11.15.2017

Eidos Therapeutics to Present Data on its Potential Treatment for Transthyretin Amyloidosis at the American Heart Association

11.09.2017

MD Anderson and BridgeBio Pharma Launch Navire Pharma to Develop Targeted Therapy for Patients with Difficult-to-Treat Cancer

10.04.2017

Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer

09.28.2017

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn to keep up with all the latest news.

Links to an external site